Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 242-249 , May 2011

Topotecan for relapsed small cell lung cancer: A systematic review and economic evaluation

  • Debbie Hartwell

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 23 8059 5632; fax: +44 23 8059 5662.
    • ,
  • Jeremy Jones

      Affiliations

    • Tel.: +44 23 8059 7056; fax: +44 23 8059 5662.
    • ,
  • Emma Loveman

      Affiliations

    • Tel.: +44 23 8056 5628; fax: +44 23 8056 5662.
    • ,
  • Petra Harris

      Affiliations

    • Tel.: +44 23 8059 5614; fax: +44 23 8059 5662.
    • ,
  • Andrew Clegg

      Affiliations

    • Tel.: +44 23 8059 5597; fax: +44 23 8059 5662.
    • ,
  • Alex Bird

      Affiliations

    • Tel.: +44 23 8059 5941; fax: +44 23 8059 5662.

Received 29 March 2010 ,Revised 12 July 2010 ,Accepted 14 July 2010.

References 

  1. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Ann Oncol. 2006;17:ii5–ii10
  2. Hyde L, Yee J, Wilson R, Patno ME. Cell type and the natural history of lung cancer. JAMA. 1965;193:52–54
  3. Rivera MP, Detterbeck FC, Loomis DP. Epidemiology and classification of lung cancer. In:  Detterbeck FC,  Rivera MP,  Socinski MA,  Rosenman JG editor. Diagnosis and treatment of lung cancer. An evidence-based guide for the practicing clinician. Philadelphia: WB Saunders Company; 2001;p. 25–44
  4. Simon GR, Turrisi A. Management of small cell lung cancer. ACCP evidence-based clinical practice guidelines (2nd ed.). Chest. 2007;132:324S–339S
  5. National Institute for Health and Clinical Excellence (NICE). The diagnosis and treatment of lung cancer. London: NICE; 2005. Clinical Guideline No. 24. Available from:www.nice.org.uk/CG024NICEguideline [accessed 03.11.08].
  6. von Pawel J. The role of topotecan in treating small cell lung cancer: second-line treatment. Lung cancer. 2003;41:S3–S8
  7. Cara S, Tannock IF. Re-treatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol. 2001;12:23–27
  8. Loveman E, Jones J, Hartwell D, et al. The clinical and cost effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2010;14(19):
  9. National Institute for Health and Clinical Excellence (NICE). Topotecan for the treatment of relapsed small-cell lung cancer. London: 2009. Technology Appraisal No. 184. Available from:www.nice.org.uk/TA184.
  10. National Institute for Health and Clinical Excellence (NICE). Appraising life-extending, end of life treatments. London: 2009. Available from:<http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf> [accessed 21.08.09].
  11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1980;47:207–214
  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  13. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. York: York Publishing Services Ltd.; 2001. CRD Report No. 4 (2nd ed.).
  14. Drummond MF, Sculpher MJ, O’Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005;
  15. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:1–158
  16. Cochrane Collaboration. Assessing risk of bias in included studies. In: Higgins J, Altman D, editors. Cochrane Handbook for Systematic Reviews of Interventions 2007. Available from:<http://www.cochrane.org/resources/handbook/Handbook5_Bias_V10.pdf>.
  17. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092
  18. O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447
  19. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19:1743–1749
  20. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667
  21. Eckardt T, von Pawel J, Hainsworth JD, et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study [abstract]. Proc Am Soc Clin Oncol. 2003;22:619
  22. Schiller J, von Pawel J, Shepherd F, et al. Topotecan (t) versus (vs) cyclophosphamide (c), doxorubicin (a) and vincristine (v) for the treatment (tx) of patients (pts) with recurrent small cell lung cancer (sclc): a phase III study [abstract]. Proc Am Soc Clin Oncol. 1998;17:1755
  23. Sugawara S, Inoue A, Yamazaki K, et al. Randomized, phase II trial comparing amrubicin with topotecan in patients (pts) with previously treated small cell lung cancer (SCLC). J Clin Oncol. 2008;26:8042
  24. Inoue A, Sugawara S, Yamazaki K, et al. Randomized Phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401–5406
  25. Chen L, Antras L, Duh M, Pickard S, Cella D, Neary M, et al. Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer? [abstract]. J Thoracic Oncol. 2007;2:S391–S392
  26. O’Brien ME, Duh MS, Chen L, Antras L, Neary M, Gralla RJ. An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomized Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial [abstract]. J Thoracic Oncol. 2007;2:S827
  27. Hycamtin: summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/Hycamtin/H-123-PI-en.pdf>; 2009 [accessed 02.02.09].
  28. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2008.
  29. GlaxoSmithKline UK. Multiple technology appraisal of topotecan for the treatment of small cell lung cancer; 2008.
  30. Main C, Bojke L, Griffin S, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2006;10(9):
  31. Oliver E, Killen J, Kiebert G, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax. 2001;56:785–790
  32. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. Available from:<http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf> [accessed 26.01.09].
  33. Richards M. Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. Available from:www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089927 [accessed 14.08.09].
  34. National Institute for Health and Clinical Excellence (NICE). Update report on the application of the ‘end-of-life’ supplementary advice in health technology appraisals. Available from:www.nice.org.uk/media/835/8E/item7endoflifetreatments.pdf [accessed 14.08.09].
  35. Raftery J. NICE and the challenges of cancer drugs. BMJ. 2009;338:271–272

PII: S0305-7372(10)00130-1

doi: 10.1016/j.ctrv.2010.07.005

Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 242-249 , May 2011

Article Tools

* Image Usage & Resolution